UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

31 Aug 2023

UCB presents new data at 35th International Epilepsy Congress (IEC) highlighting important advancements across Fintepla[®]▼(fenfluramine) oral solution and broader epilepsies portfolio

Read More
27 Jul 2023

UCB now at the inflection point – ready to start a new phase of growth

Read More
18 Jul 2023

UCB Announces EU Regulatory Filing for Bimekizumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

Read More
30 Jun 2023

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio at 9th Congress of the European Academy of Neurology (EAN) Meeting

Read More
27 Jun 2023

UCB announces U.S. FDA approval of RYSTIGGO[®] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

Read More
26 Jun 2023

UCB Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab

Read More

Stay up-to-date on the latest news and information from UCB